FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - NYSE Delayed Price. Currency in USD
37.41
-0.02 (-0.05%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close37.43
Open37.54
Bid37.44 x 900
Ask37.47 x 800
Day's Range37.36 - 37.54
52 Week Range30.99 - 53.40
Volume215,508
Avg. Volume236,336
Market Cap22.387B
Beta (3Y Monthly)1.93
PE Ratio (TTM)10.13
EPS (TTM)3.69
Earnings DateN/A
Forward Dividend & Yield0.66 (1.80%)
Ex-Dividend Date2019-05-17
1y Target Est47.03
Trade prices are not sourced from all markets
  • Moody's9 days ago

    U.S. Renal Care, Inc (New) -- Moody's assigns a Caa2 rating to the senior unsecured notes of US Renal Care, Inc. (NEW)

    Moody's Investors Service ("Moody's") today assigned a Caa2 rating to U.S. Renal Care, Inc.'s (NEW) ("U.S. Renal") new senior unsecured notes. There is no change to the company's existing ratings, including the B3 Corporate Family Rating, B3-PD Probability of Default Rating, and B2 ratings on the company's new senior secured revolving credit facility and term loan. Moody's expects that the proceeds from these notes, along with the company's proposed credit facility and equity, will be used to finance the $2.7 billion leveraged buyout of the company by a consortium of private equity investors led by Bain Capital and Summit Partners.

  • Reuters10 days ago

    INSIGHT-Will Europe's clampdown on faulty medical devices hurt patients?

    When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. "Now it has flipped," said Bill Colone, CEO of San Clemente-based Spinal Singularity, which hopes to launch a 'smart' catheter for men with spinal injuries or disease early next year after squeezing in its application under the old European rules. Colone is part of a chorus of industry voices warning that a switch to stricter European rules governing medical devices, due to come into force a year from now, will slow or even halt the release of products in Europe that could transform patients' lives.

  • Is Cara Therapeutics a Buy Now?
    Motley Fool14 days ago

    Is Cara Therapeutics a Buy Now?

    A pivotal trial for the company's lead candidate was an unequivocal success.

  • Moody's17 days ago

    U.S. RENAL CARE, INC. (NEW) -- Moody's assigns a B3 CFR to US Renal Care, Inc. (NEW); outlook stable

    The rating agency also assigned a B2 rating to the company's new senior secured revolving credit facility and term loan. Moody's expects that the proceeds from the proposed credit facility, along with the issuance of junior debt capital and equity, will be used to finance the $2.7 billion leveraged buyout of the company by a consortium of private equity investors led by Bain Capital and Summit Partners.

  • Cara Shares Up on Positive Phase III Data for Itchiness Drug
    Zacks17 days ago

    Cara Shares Up on Positive Phase III Data for Itchiness Drug

    Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

  • PR Newswire18 days ago

    Fresenius Medical Care Breaks Ground on Knoxville Distribution Center

    KNOXVILLE, Tenn., May 29, 2019 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, today celebrated the groundbreaking for a new distribution center in Knoxville, Tenn., which will help support the company's efforts to increase the number of patients with kidney failure choosing home dialysis.

  • Moody's24 days ago

    Fresenius Finance Ireland II Plc -- Moody's announces completion of a periodic review of ratings of Fresenius SE & Co. KGaA

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of FME.DE earnings conference call or presentation 2-May-19 1:30pm GMT

    Q1 2019 Fresenius Medical Care AG & Co KGaA Earnings Call

  • Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
    Zackslast month

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    Fresenius Medical (FMS) gains from solid international revenues in Q1.

  • Reuterslast month

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medical Care AG & Co. KGaA  - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (''Fresenius'' or the ''Company'') (FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • Fresenius Medical Care to pay $231M to resolve bribery charges
    American City Business Journals2 months ago

    Fresenius Medical Care to pay $231M to resolve bribery charges

    Fresenius Medical Care, a dialysis clinic operator, agreed Friday to pay $231 million in penalties to resolve allegations it paid bribes to win business deals in several countries, including Angola and Saudi Arabia.

  • Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?
    Insider Monkey3 months ago

    Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Reuters3 months ago

    Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges

    Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges.

  • Reuters3 months ago

    Fresenius Medical Care says U.S. settlement will not affect 2019, 2020 results

    Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial ...

  • MarketWatch3 months ago

    Fresenius Medical Care to pay $231 million to settle bribery charges

    The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.

  • Fresenius Medical to Make Huge Investments, Competition Rife
    Zacks3 months ago

    Fresenius Medical to Make Huge Investments, Competition Rife

    Fresenius Medical (FMS) is likely to make huge investments in India and China.

  • Fresenius Medical's New Hemodialysis Software Gets FDA Nod
    Zacks3 months ago

    Fresenius Medical's New Hemodialysis Software Gets FDA Nod

    Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

  • Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
    Zacks3 months ago

    Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

    Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

  • Should Value Investors Pick Fresenius Medical (FMS) Stock?
    Zacks3 months ago

    Should Value Investors Pick Fresenius Medical (FMS) Stock?

    Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?
    Simply Wall St.3 months ago

    How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?

    If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...